Intest Res.  2015 Apr;13(2):145-152. 10.5217/ir.2015.13.2.145.

Inhibitory Effect of Metformin Therapy on the Incidence of Colorectal Advanced Adenomas in Patients With Diabetes

• Kim YH
• Noh R
• Cho SY
• Park SJ
• Jeon SM
• Shin HD
• Kim SB
• Shin JE

• KMID: 2284881
• DOI: http://doi.org/10.5217/ir.2015.13.2.145

Abstract

BACKGROUND/AIMS
Metformin use has been associated with decreased colorectal cancer risk and mortality among diabetic patients. Recent research suggests that metformin use may decrease the incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. This study aimed to assess the clinical effect of metformin use on the development of colorectal adenomas in diabetic patients without previous colorectal cancer.
METHODS
Among 604 consecutive diabetic patients who underwent colonoscopic surveillance after initial colonoscopy between January 2002 and June 2012, 240 patients without previous colorectal cancer were enrolled in this study and were divided in two groups: 151 patients receiving metformin and 89 patients not receiving metformin. Patient demographics and clinical characteristics as well as the colorectal adenoma incidence rate were retrospectively analyzed.
RESULTS
The incidence rate of total colorectal adenomas was not different according to metformin use (P=0.349). However, the advanced adenoma incidence rate was significantly lower in the metformin group compared with the non-metformin group (relative risk [RR], 0.09; P=0.011). Metformin use was independently associated with a decreased incidence of advanced colorectal adenomas after adjustment for clinically relevant factors (RR, 0.072; P=0.016). In addition, the cumulative development rate of advanced adenomas during follow-up was significantly lower in the metformin group compared with the non-metformin group (P=0.007).
CONCLUSIONS
Metformin use in diabetic patients without previous colorectal cancer is associated with a lower risk of advanced colorectal adenomas.

Keyword

Advanced colorectal adenoma; Diabetes mellitus; Incidence; Metformin

MeSH Terms

Adenoma*
Colonoscopy
Colorectal Neoplasms
Demography
Diabetes Mellitus
Follow-Up Studies
Humans
Incidence*
Metformin*
Mortality
Retrospective Studies
Metformin

Figure

• 

  Fig. 1 Cumulative development rates of advanced adenomas according to metformin use. The rates were significantly lower in the metformin group compared with the non-metformin group during follow-up (F/U) (P=0.007).

Reference

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62:10–29. PMID: 22237781.

2. Jung KW, Park S, Kong HJ, et al. Cancer statistics in Korea: incidence, mortality and survival in 2006-2007. J Korean Med Sci. 2010; 25:1113–1121. PMID: 20676319.

3. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319:525–532. PMID: 2841597.

4. Maisonneuve P, Botteri E, Lowenfels AB. Five-year risk of colorectal neoplasia after negative colonoscopy. N Engl J Med. 2008; 359:2611–2612. PMID: 19090030.

5. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Post-load plasma glucose and cancer mortality in middle-aged men and women. 12-year follow-up findings of the Chicago Heart Association Detection Project in Industry. Am J Epidemiol. 1990; 131:254–262. PMID: 2296978.

6. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol. 2003; 157:1092–1100. PMID: 12796045.

7. Weiderpass E, Gridley G, Nyren O, Ekbom A, Persson I, Adami HO. Diabetes mellitus and risk of large bowel cancer. J Natl Cancer Inst. 1997; 89:660–661. PMID: 9150194.

8. Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004; 159:1160–1167. PMID: 15191933.

9. Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003; 21:433–440. PMID: 12560431.

10. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52:1766–1777. PMID: 19572116.

11. Dehal AN, Newton CC, Jacobs EJ, Patel AV, Gapstur SM, Campbell PT. Impact of diabetes mellitus and insulin use on survival after colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol. 2012; 30:53–59. PMID: 22124092.

12. Seow A, Yuan JM, Koh WP, Lee HP, Yu MC. Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study. J Natl Cancer Inst. 2006; 98:135–138. PMID: 16418516.

13. Atchison EA, Gridley G, Carreon JD, Leitzmann MF, McGlynn KA. Risk of cancer in a large cohort of US veterans with diabetes. Int J Cancer. 2011; 128:635–643. PMID: 20473855.

14. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005; 17:596–603. PMID: 16226444.

15. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog. 2010; 49:662–671. PMID: 20564343.

16. Tomimoto A, Endo H, Sugiyama M, et al. Metformin suppresses intestinal polyp growth in Apc^Min/+ mice. Cancer Sci. 2008; 99:2136–2141. PMID: 18803638.

17. Lee JH, Jeon SM, Hong SP, Cheon JH, Kim TI, Kim WH. Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. Dig Liver Dis. 2012; 44:1042–1047. PMID: 22789400.

18. Garrett CR, Hassabo HM, Bhadkamkar NA, et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer. 2012; 106:1374–1378. PMID: 22421948.

19. Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer. 2012; 131:752–759. PMID: 21913184.

20. Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care. 2011; 34:2323–2328. PMID: 21949223.

21. Kanadiya MK, Gohel TD, Sanaka MR, Thota PN, Shubrook JH Jr. Relationship between type-2 diabetes and use of metformin with risk of colorectal adenoma in an American population receiving colonoscopy. J Diabetes Complications. 2013; 27:463–466. PMID: 23755906.

22. Cho YH, Ko BM, Kim SH, et al. Does metformin affect the incidence of colonic polyps and adenomas in patients with type 2 diabetes mellitus? Intest Res. 2014; 12:139–145. PMID: 25349581.

23. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008; 8:915–928. PMID: 19029956.

24. Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle. 2009; 8:88–96. PMID: 19106626.

25. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27:3576–3586. PMID: 18212742.

26. Buzzai M, Jones RG, Amaravadi RK, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res. 2007; 67:6745–6752. PMID: 17638885.

27. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila). 2010; 3:1077–1083. PMID: 20810669.

28. Chung YW, Han DS, Park KH, Eun CS, Yoo KS, Park CK. Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea. Dis Colon Rectum. 2008; 51:593–597. PMID: 18219529.

29. Higurashi T, Takahashi H, Endo H, et al. Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer. 2012; 12:118. PMID: 22443173.

30. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003; 348:891–899. PMID: 12621133.

31. Campbell PT, Deka A, Jacobs EJ, et al. Prospective study reveals associations between colorectal cancer and type 2 diabetes mellitus or insulin use in men. Gastroenterology. 2010; 139:1138–1146. PMID: 20633560.

32. Okumura T. Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs. J Gastroenterol. 2010; 45:1097–1102. PMID: 20824291.